title: [A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor].
abstract: Overexpression of cyclooxygenase-2 (COX-2) has been associated with hepatocarcinogenesis. Inhibitors of COX-2 have proapoptotic and antiproliferative effects on malignant tumors and inhibit tumor invasion to the surrounding tissues. We report here a case of complete regression of advanced hepatocellular carcinoma (HCC) during COX-2 inhibitor administration. An eighty-year-old female was diagnosed as an advanced HCC, which was associated with HCV infection. She received COX-2 inhibitor for 3 months due to degenerative arthritis of both knees. Tumor enhancement on arterial phase CT completely disappeared without specific treatment for the HCC, and the tumor size decreased on the follow-up CT scan.
authors.affiliation: Institute for Digestive Research, Department of Internal Medicine, Soon Chun Hyang University, College of Medicine, Seoul, Korea.
authors.forename: Hae Jung
authors.initials: HJ
authors.lastname: Song
authors.forename: Yun Soo
authors.initials: YS
authors.lastname: Kim
authors.forename: Chang Hee
authors.initials: CH
authors.lastname: Han
authors.forename: Jae Young
authors.initials: JY
authors.lastname: Jang
authors.forename: Jung Hoon
authors.initials: JH
authors.lastname: Kim
authors.forename: Young Koog
authors.initials: YK
authors.lastname: Cheon
authors.forename: Young Seok
authors.initials: YS
authors.lastname: Kim
authors.forename: Jong Ho
authors.initials: JH
authors.lastname: Moon
authors.forename: Young Deok
authors.initials: YD
authors.lastname: Cho
authors.forename: Chan Sup
authors.initials: CS
authors.lastname: Shim
authors.forename: Kui Hyang
authors.initials: KH
authors.lastname: Kwon
authors.forename: Boo Sung
authors.initials: BS
authors.lastname: Kim
mesh_terms: D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004008:Diclofenac / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007783:Lactones / Q000008:administration & dosage / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy*; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D013450:Sulfones / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D004008:Diclofenac; D000068579:Celecoxib; C056498:aceclofenac